Lombard Odier Asset Management (Switzerland)’s Rubius Therapeutics, Inc RUBY Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-259,918	Closed	-$1.43M	–	339
2022 Q1	$1.43M	Sell	259,918 -7,735	-3%	-$49.1K	0.11%	113
2021 Q4	$2.59M	Buy	267,653 +22,640	+9%	+$314K	0.17%	83
2021 Q3	$4.38M	Buy	245,013 +22,746	+10%	+$495K	0.27%	79
2021 Q2	$5.43M	Buy	222,267 +58,265	+36%	+$1.46M	0.28%	80
2021 Q1	$4.35M	Buy	+164,002	New	+$2.4M	0.29%	77

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s RUBY Position: Q2 2022 in Review

Lombard Odier Asset Management (Switzerland) sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 259,918 shares — an estimated $1.43M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in RUBY in Q1 2021 and held it in 5 quarters. The position peaked at $5.43M in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Lombard Odier Asset Management (Switzerland) reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 259,918 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $1.43M.
Lombard Odier Asset Management (Switzerland) first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 5 quarters.
Lombard Odier Asset Management (Switzerland)'s Rubius Therapeutics, Inc position peaked at $5.43M in Q2 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2022, filed 15 Aug 2022.